These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7688627)
1. Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma. Avilés A; Narváez BR; Díaz-Maqueo JC; Guzmán R; Talavera A; García EL Leuk Lymphoma; 1993 Mar; 9(4-5):377-80. PubMed ID: 7688627 [TBL] [Abstract][Full Text] [Related]
2. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Cortes JE; Talpaz M; Cabanillas F; Seymour JF; Kurzrock R Blood; 1995 May; 85(9):2516-20. PubMed ID: 7537119 [TBL] [Abstract][Full Text] [Related]
4. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181 [TBL] [Abstract][Full Text] [Related]
5. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615 [TBL] [Abstract][Full Text] [Related]
7. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. Weeks JC; Yeap BY; Canellos GP; Shipp MA J Clin Oncol; 1991 Jul; 9(7):1196-203. PubMed ID: 1710656 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of primary mediastinal large B-cell lymphomas]. Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753 [TBL] [Abstract][Full Text] [Related]
9. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. Winter JN Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375 [TBL] [Abstract][Full Text] [Related]
10. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. Dana BW; Dahlberg S; Miller TP; Hartsock RJ; Balcerzak S; Coltman CA; Carden JO; Hartley K; Fisher RI J Clin Oncol; 1990 Jul; 8(7):1155-62. PubMed ID: 1694233 [TBL] [Abstract][Full Text] [Related]
11. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Avilés A; Zepeda G; Díaz-Maqueo JC; Rodriguez L; Guzmán R; García EL; Talavera A Leuk Lymphoma; 1992 May; 7(1-2):135-8. PubMed ID: 1472924 [TBL] [Abstract][Full Text] [Related]
12. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. El-Sharkawi D; Basu S; Ocampo C; Qian W; D'Sa S; Hoskin PJ; Ardeshna KM Leuk Lymphoma; 2012 Oct; 53(10):1949-52. PubMed ID: 22462615 [TBL] [Abstract][Full Text] [Related]
13. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777 [TBL] [Abstract][Full Text] [Related]
15. [M-BACOD in advanced case of non-Hodgkin's lymphoma]. Itami J; Ogata H; Shimizu K; Nemoto K; Yasuda S; Yoshida H; Mikata A; Arimizu N Gan No Rinsho; 1990 Mar; 36(4):499-504. PubMed ID: 1690824 [TBL] [Abstract][Full Text] [Related]
16. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors]. Sancho JM; Ribera JM; Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451 [TBL] [Abstract][Full Text] [Related]
17. The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy. Lishner M; Slingerland J; Theresa C; Sutcliffe SB Leuk Lymphoma; 1994 Mar; 13(1-2):131-6. PubMed ID: 7517744 [TBL] [Abstract][Full Text] [Related]
19. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). Skarin AT; Canellos GP; Rosenthal DS; Case DC; MacIntyre JM; Pinkus GS; Moloney WC; Frei E J Clin Oncol; 1983 Feb; 1(2):91-8. PubMed ID: 6199472 [TBL] [Abstract][Full Text] [Related]
20. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Rodriguez J; Pugh WC; Romaguera JE; Luthra R; Hagemeister FB; McLaughlin P; Rodriguez MA; Swan F; Cabanillas F Ann Oncol; 1994 Nov; 5(9):847-9. PubMed ID: 7848887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]